These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7527960)

  • 1. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group.
    Transplant Proc; 1994 Dec; 26(6):3260-3. PubMed ID: 7527960
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract]   [Full Text] [Related]  

  • 3. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
    Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
    Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
    [No Abstract]   [Full Text] [Related]  

  • 6. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract]   [Full Text] [Related]  

  • 8. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A.
    Mueller AR; Platz KP; Blumhardt G; Bechstein WO; Steinmüller T; Christe W; Hopf U; Lobeck H; Neuhaus P
    Transplant Proc; 1995 Feb; 27(1):1117-20. PubMed ID: 7533359
    [No Abstract]   [Full Text] [Related]  

  • 9. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
    Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
    Sher LS; Cosenza CA; Petrovic LM; Rojter S; Hoffman A; Lopez RR; Meehan M; Pan SH; Vierling J; Makowka L
    Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
    [No Abstract]   [Full Text] [Related]  

  • 11. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
    Jacob DA; Neumann UP; Bahra M; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
    Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P
    Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.
    Lancet; 1994 Aug; 344(8920):423-8. PubMed ID: 7520105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
    Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
    Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.
    McDiarmid SV; Busuttil RW; Ascher NL; Burdick J; D'Alessandro AM; Esquivel C; Kalayoglu M; Klein AS; Marsh JW; Miller CM
    Transplantation; 1995 Feb; 59(4):530-6. PubMed ID: 7533345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
    Mueller AR; Platz KP; Bechstein WO; Blumhardt G; Lobeck H; Hop U; Neuhaus P
    Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
    [No Abstract]   [Full Text] [Related]  

  • 17. [Value of a powerful initial immunosuppression after liver transplantation. Prospective study of 60 cases].
    Cherqui D; Duvoux C; Charlotte F; Humeres R; Lauzet JY; Métreau JM; Salvat A; Rotman N; Julien M; Fagniez PL
    Gastroenterol Clin Biol; 1994; 18(2):115-22. PubMed ID: 8013792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up.
    Jonas S; Neuhaus R; Junge G; Klupp J; Theruvat T; Langrehr JM; Settmacher U; Neuhaus P
    Int Immunopharmacol; 2005 Jan; 5(1):125-8. PubMed ID: 15589470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin monotherapy (after 3 months) in liver transplant patients: a prospective randomized trial.
    Romani F; Belli LS; De Carlis L; Rondinara GF; Alberti A; Sansalone CV; Bellati G; Zavaglia C; Fesce E; Ideo G
    Transplant Proc; 1994 Oct; 26(5):2683-5. PubMed ID: 7940840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.